Oncoinvent AS

📍 Oslo, Norway🗓 Founded 2010👥 46 employees💰 Last funded 2020
Pharmaceutical Manufacturing🌐 oncoinvent.com
Website LinkedIn
Oncoinvent is a clinical stage company committed to developing new innovative radiopharmaceutical products for better treatment options for cancer patients. Radspherin®, the company’s lead product candidate is a novel alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities. Radspherin® has shown strong and consistent anticancer activity at essentially non-toxic doses in preclinical studies and is anticipated to potentially treat several forms of metastatic cancer. Situated in Oslo, Oncoinvent’s main offices include modern laboratory facilities suitable for cGMP and radiopharmaceutical manufacture for clinical trials and research. The development programs of the company include radiotherapeutic and radioimmunotherapeutic products with focus on alpha-emitting radionuclides for treatment of various solid cancers. Oncoinvent – Innovations for better cancer care.
2
Total investors
0
Early stage
0
Mid stage
1
Late stage
2010
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Norway
2
Frequently asked questions
Who invested in Oncoinvent AS?
Oncoinvent AS has 2 investors on record on gritt.io and 1 late-stage investors.
When did Oncoinvent AS last raise funding?
The most recent investment in Oncoinvent AS recorded on gritt.io was in 2020.
When was Oncoinvent AS founded?
Oncoinvent AS was founded in 2010.
What industry is Oncoinvent AS in?
Oncoinvent AS operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Oncoinvent AS based?
Oncoinvent AS is headquartered in Oslo, Norway.